Precigen Inc. (PGEN)

AI Score

Unlock

1.80

0.00 (0.00%)

At close: Mar 21, 2025, 3:59 PM

0.00% (1D)

Bid	1.81
Market Cap	527.16M
Revenue (ttm)	4.44M
Net Income (ttm)	-142.66M
EPS (ttm)	-0.47
PE Ratio (ttm)	-3.83
Forward PE	-5.71
Analyst	Buy

Ask	1.84
Volume	1,747,225
Avg. Volume (20D)	2,057,289
Open	1.81
Previous Close	1.80
Day's Range	1.78 - 1.96
52-Week Range	0.65 - 2.17
Beta	1.58

About PGEN

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic comp...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 8, 2013

Employees 202

Stock Exchange NASDAQ

Ticker Symbol PGEN

Website https://www.precigen.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 233.33% from the latest price.

Stock Forecasts

Earnings Surprise

Precigen has released their quartely earnings on Mar 19, 2025:

Revenue of $1.19M misses estimates by $40K, with -3.09% YoY decline.

EPS of -0.06 misses estimates by 0.00, with 53.85% YoY growth.

Next Earnings Release

Precigen Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+18.58%

Precigen shares are trading higher after HC Wainwr... Unlock content with Pro Subscription

2 months ago

+28.47%

Precigen shares are trading higher after the company announced it's seeking FDA priority review for its gene therapy targeting rare respiratory disease.

News

4 days ago · seekingalpha.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC...

4 days ago · zacks.com

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.

3 weeks ago · seekingalpha.com

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be...

1 month ago · zacks.com

Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?

Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 2...

2 months ago · zacks.com

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.